Vaccines have been a central focus for Trump's health leaders, but large-cap players aren't feeling the sting.

The Department of Health and Human Services, which oversees FDA and other health agencies, did not immediately respond to a ...

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full approval, sending the drugmaker's shares soaring and easing concerns around the ...

Sanofi has reported positive results a year ... CureVac and partner GSK are, meanwhile, also developing an mRNA-based flu vaccine, but are a little further back in development, as their shot ...

Jean-François Toussaint, Sanofi's global head of vaccines R ... track designation from the FDA for a preclinical-stage mRNA-based vaccine candidate that is due to start a phase 1/2 trial in ...

The Trump administration has reportedly disrupted over 100 clinical trials. Science News spoke to researchers about the impacts on four of them.

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

South Korean vaccine developer SK bioscience has won a final ruling in a patent dispute with Moderna (Nasdaq: MRNA) over key ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key regulatory hurdle at its flagship production plant in the United Kingdom.

CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older ...